Abbvie-Header Abbvie-Header


Find Clinical Drug Development Pipelines & Deals | PipelineProspector


All Data

Filters Filter refresh
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Vidofludimus calcium anhydrous

            Therapeutic Area: Immunology Product Name: IMU-838

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Immunic Therapeutics

            Deal Size: $17.2 million Upfront Cash: Undisclosed

            Deal Type: Agreement March 31, 2021


            The acquisition of the royalties will enable Immunic to realize the full market potential of IMU-838, not only as a treatment for RRMS but also as a potential new therapeutic option for ulcerative colitis, Crohn’s disease, COVID-19, and primary sclerosing cholangitis.